CN102014925B - 氟维司群配制剂 - Google Patents

氟维司群配制剂 Download PDF

Info

Publication number
CN102014925B
CN102014925B CN2009801081573A CN200980108157A CN102014925B CN 102014925 B CN102014925 B CN 102014925B CN 2009801081573 A CN2009801081573 A CN 2009801081573A CN 200980108157 A CN200980108157 A CN 200980108157A CN 102014925 B CN102014925 B CN 102014925B
Authority
CN
China
Prior art keywords
poloxamer
fulvestrant
polyethylene glycol
preparaton
dihydrolipoic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2009801081573A
Other languages
English (en)
Chinese (zh)
Other versions
CN102014925A (zh
Inventor
N·R·帕勒普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kay Hua Co
Original Assignee
Scidose LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scidose LLC filed Critical Scidose LLC
Publication of CN102014925A publication Critical patent/CN102014925A/zh
Application granted granted Critical
Publication of CN102014925B publication Critical patent/CN102014925B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2009801081573A 2008-03-07 2009-03-05 氟维司群配制剂 Expired - Fee Related CN102014925B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6856008P 2008-03-07 2008-03-07
US61/068,560 2008-03-07
PCT/US2009/001437 WO2009111057A2 (en) 2008-03-07 2009-03-05 Fulvestrant formulations

Publications (2)

Publication Number Publication Date
CN102014925A CN102014925A (zh) 2011-04-13
CN102014925B true CN102014925B (zh) 2013-02-06

Family

ID=41054291

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801081573A Expired - Fee Related CN102014925B (zh) 2008-03-07 2009-03-05 氟维司群配制剂

Country Status (8)

Country Link
US (7) US9180088B2 (enExample)
EP (1) EP2249839A4 (enExample)
JP (1) JP2011514349A (enExample)
KR (1) KR20100121505A (enExample)
CN (1) CN102014925B (enExample)
CA (1) CA2716576A1 (enExample)
WO (1) WO2009111057A2 (enExample)
ZA (1) ZA201006315B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101677987A (zh) * 2007-06-22 2010-03-24 赛多斯有限责任公司 不含吐温80的多西他赛的增溶制剂
JP2011514349A (ja) 2008-03-07 2011-05-06 サイドース・エルエルシー フルベストラント配合物
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US8476310B2 (en) 2009-10-19 2013-07-02 Scidose Llc Docetaxel formulations with lipoic acid
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
JP4929423B2 (ja) 2010-07-22 2012-05-09 日本碍子株式会社 成形体、及び、成形体の製造方法
CA2836831C (en) 2011-05-20 2015-06-02 Capital, Business Y Gestion De Finanzas S.L. Pharmaceutical composition
CN102600064A (zh) * 2012-03-31 2012-07-25 西安力邦制药有限公司 氟维司群或其衍生物缓释制剂及其制备方法
CN102600073B (zh) * 2012-03-31 2014-01-01 莱普德制药有限公司 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法
CN102600065B (zh) * 2012-03-31 2014-08-13 莱普德制药有限公司 一种氟维司群或其衍生物油性制剂及其制备方法
US11179468B2 (en) 2012-04-09 2021-11-23 Eagle Pharmaceuticals, Inc. Fulvestrant formulations
CA2869377C (en) * 2012-04-09 2022-11-08 Scidose, Llc Fulvestrant formulations
US20160060288A1 (en) * 2013-04-18 2016-03-03 Xi'anlibang Pharmaceutical Technology Co., Ltd. Ester derivatives of 7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-estra-1,3,5(10)-triene-3,17beta-diol having anticancer activity and preparation method thereof
HUP1300646A2 (en) * 2013-11-12 2015-05-28 Druggability Technologies Ip Holdco Jersey Ltd Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
US9271990B2 (en) 2014-02-14 2016-03-01 Fresenius Kabi Usa, Llc Fulvestrant formulations
IL285928B2 (en) 2016-05-06 2025-06-01 Eagle Pharmaceuticals Inc Fulvestrant formulations and methods of their use
CN109152785B (zh) 2016-05-31 2021-02-09 富士胶片株式会社 医药组合物
CN107789320B (zh) * 2016-08-31 2021-06-22 鲁南制药集团股份有限公司 一种氟维司群缓释注射液及其制备工艺
CA3032912A1 (en) * 2017-05-23 2018-11-29 Kashiv Biosciences, Llc High-concentration fulvestrant compositions
BR112020009141A2 (pt) * 2017-11-08 2020-10-27 Eagle Pharmaceuticals, Inc. método para tratar câncer de mama num indivíduo
KR20220079472A (ko) * 2020-12-04 2022-06-13 주식회사 삼양홀딩스 풀베스트란트의 서방형 약학 조성물 및 그 제조 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007033434A1 (en) * 2005-09-26 2007-03-29 Hospira Australia Pty Ltd Fulvestrant formulation

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2087721B (en) * 1980-11-20 1984-01-25 Beecham Group Ltd Injectable antibiotic formulations stabilised with glycofurol
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
DE3406497A1 (de) 1984-02-23 1985-09-05 Mueller Bernhard Willi Werner Hochdisperse pharmazeutische mehrkomponentensysteme und verfahren zu ihrer herstellung
US5462726A (en) 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
GB9525194D0 (en) * 1995-12-12 1996-02-07 Zeneca Ltd Pharmaceutical composition
US20060264357A1 (en) 1997-04-22 2006-11-23 Zikria Bashir A Capillary membrane stabilization and reduction of tissue injury through use of biodegradable macromolecules with antioxidants and/or other chemicals
DK0999838T3 (da) 1997-07-29 2002-07-08 Upjohn Co Selv-emulgerende formulering for lipofile forbindelser
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
KR20020013174A (ko) 2000-08-11 2002-02-20 민경윤 경구 흡수율이 낮은 약물의 흡수율을 증가시키기 위한경구용 조성물
EP1345589B1 (en) 2000-11-29 2007-06-27 Lyotropic Therapeutics, Inc. Solvent systems for pharmaceutical agents
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
EP1258243A1 (en) 2001-05-16 2002-11-20 N.V. Nutricia Lipoic acid for suppressing undesired haematological effects of chemotherapy and/or radiotherapy
GB0116620D0 (en) 2001-07-07 2001-08-29 Astrazeneca Ab Formulation
US20040047835A1 (en) * 2002-09-06 2004-03-11 Cell Therapeutics, Inc. Combinatorial drug therapy using polymer drug conjugates
AU2004265238A1 (en) 2003-06-11 2005-02-24 Novacea, Inc. Treatment of lung cancer with active vitamin D compounds in combination with other treatments
CA2530407A1 (en) 2003-07-23 2005-02-03 The Regents Of The University Of California Penetration enhancer combinations for transdermal delivery
US20050090551A1 (en) 2003-10-27 2005-04-28 Board Of Trustees Of Southern Illinois University Therapeutic use of methionine for the treatment or prevention of mucositis
US20060003002A1 (en) 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
KR20050099311A (ko) 2004-04-09 2005-10-13 에이엔에이치 케어연구소(주) 주사제용 항암제 조성물
WO2006037031A2 (en) * 2004-09-27 2006-04-06 Valentis, Inc. Formulations and methods for treatment of inflammatory diseases
MX2007009748A (es) 2005-02-14 2007-09-26 Univ Florida State Res Found Composiciones de taxano sustituidas con esteres ciclopropilicos en c10.
GB0517092D0 (en) 2005-08-19 2005-09-28 Novartis Ag New compositions containing taxane derivatives
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US8338416B2 (en) 2006-03-16 2012-12-25 Pharmacylics, Inc. Indole derivatives as inhibitors of histone deacetylase
US20100098735A1 (en) 2006-10-05 2010-04-22 Rajesh Jain Injectable depot compositions and its process of preparation
CN101677987A (zh) 2007-06-22 2010-03-24 赛多斯有限责任公司 不含吐温80的多西他赛的增溶制剂
US20090181068A1 (en) 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
US8586625B2 (en) 2008-01-16 2013-11-19 Anwar Rayan Derivatives of taxol and closely related compounds
JP2011514349A (ja) 2008-03-07 2011-05-06 サイドース・エルエルシー フルベストラント配合物
EP2276755A4 (en) 2008-03-31 2011-05-04 Univ Florida State Res Found C (10) -ETHYESTER- AND C (10) -CYCLOPROPYLESTER-SUBSTITUTED TAXANES
KR20100018741A (ko) 2008-08-07 2010-02-18 신풍제약주식회사 도세탁셀 함유 항암용 주사제 조성물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007033434A1 (en) * 2005-09-26 2007-03-29 Hospira Australia Pty Ltd Fulvestrant formulation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Bross. et al.Fulvestrant in Postmenopausal Women with Advanced Breast Cancer.《Clinical Cancer Research》.2003,4309-4317. *
online.Castor Oil MSDS.《Science Lab.com》.2006,全文. *
online.Scientific Discussion.《EMEA》.2006,全文. *
杜文婷等.紫杉醇水溶性衍生物的研究进展.《中国现代应用药学》.2005,(第01期),29-31. *

Also Published As

Publication number Publication date
US10363259B2 (en) 2019-07-30
US20220387446A1 (en) 2022-12-08
US20180289722A1 (en) 2018-10-11
US20240082264A1 (en) 2024-03-14
JP2011514349A (ja) 2011-05-06
US20160058773A1 (en) 2016-03-03
EP2249839A2 (en) 2010-11-17
US20090227549A1 (en) 2009-09-10
WO2009111057A2 (en) 2009-09-11
CN102014925A (zh) 2011-04-13
US20200188411A1 (en) 2020-06-18
KR20100121505A (ko) 2010-11-17
EP2249839A4 (en) 2013-10-16
US20210260076A1 (en) 2021-08-26
WO2009111057A3 (en) 2010-03-04
ZA201006315B (en) 2012-02-29
WO2009111057A4 (en) 2010-04-29
CA2716576A1 (en) 2009-09-11
US9180088B2 (en) 2015-11-10
US9801892B2 (en) 2017-10-31

Similar Documents

Publication Publication Date Title
CN102014925A (zh) 氟维司群配制剂
JP5709826B2 (ja) 治療用組成物
EP2666463A1 (en) Stabilized liquid composition comprising pemetrexed
KR101679380B1 (ko) 두타스테리드를 포함하는 약학적 조성물 및 이를 포함하는 캡슐 제형
US9662340B2 (en) Testosterone gel compositions and related methods
JP2009509942A (ja) フルベストラント製剤
US20210145846A1 (en) High-concentration fulvestrant compositions
EP2836199A1 (en) Fulvestrant formulations
WO2005074890A1 (en) Semisolid matrix pharmaceutical formulations
WO2022119383A1 (ko) 풀베스트란트의 서방형 약학 조성물 및 그 제조 방법
KR100299942B1 (ko) 비페닐디메칠디카르복실레이트의액제
KR102794126B1 (ko) 페메트렉시드 제제
AU2014268234B2 (en) Therapeutic compositions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: KINGDOM CORP.

Free format text: FORMER OWNER: SCIDOSE LLC

Effective date: 20130528

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20130528

Address after: American Connecticut

Patentee after: Kay Hua Co

Address before: Massachusetts USA

Patentee before: Scidose LLC

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130206

Termination date: 20160305